Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRMD vs OGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CRMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)
CRMD Overall Winner
6-Pillar Tally: CRMD 5 – 1 OGEN
Matrix Metrics: CRMD 10 – 0 OGEN
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas OGEN carries 41.7/100 (SELL) at $0.19 (N/M Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile OGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CRMD vs OGEN
CRMD
Head-to-Head Winner
CorMedix Inc.
$4.92
+5.47% 1D
Market Cap
$384.7M
TTM Revenue
$1.05B
Forward P/E
49.0x
Beta / 30D Vol
1.20β · 107% Vol
Unified Composite Score
53.2
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
OGEN
Oragenics Inc.
$0.19
-7.36% 1D
Market Cap
$1.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.18β · 153% Vol
Unified Composite Score
41.7
SELL
Tech 25.0
Fund 46.0
Flow 50.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CRMD 5 – 1 OGEN)
1. Valuation Multiples
CRMD
Forward P/E
49.0x
N/M
Trailing P/E
2.4x
N/M
PEG Ratio
3.79x
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
CRMD
Revenue Growth (YoY)
-47.7%
-91.3%
Earnings Growth (YoY)
+6.7%
+0.0%
TTM Revenue (USD)
$1.05B
N/A
Market Cap
$384.7M
$1.6M
3. Profitability & Quality
CRMD
Gross Margin
87.4%
N/A
Operating Margin
41.0%
0.0%
Net Profit Margin
15.5%
0.0%
Return on Equity (ROE)
15.3%
-1307.1%
4. Balance Sheet & Cash Flow
CRMD
Cash Generation (TTM)
$785M
N/A
Cash Flow Margin
74.6%
N/A
Net Cash / Leverage
$535M Net Cash
$6.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OGEN
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
56.3% (25th %ile)
N/A (N/A)
Put/Call OI Skew
0.69x (Call-Skewed)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
CRMD
OpEx & R&D Intensity
46.4% of Rev ($488M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CRMD (10) vs OGEN (0)| Institutional Metric | CRMD | OGEN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $384.7M | $1.6M | CRMD | |
| Trailing P/E Ratio | 2.4x | N/M | CRMD | |
| Forward P/E Ratio | 49.0x | N/M | CRMD | |
| Revenue Growth (YoY) | -47.7% | -91.3% | CRMD | |
| Operating Margin (TTM) | 41.0% | 0.0% | CRMD | |
| Net Profit Margin | 15.5% | 0.0% | CRMD | |
| Return on Equity (ROE) | 15.3% | -1307.1% | CRMD | |
| 52-Week Range Position | 3% ($5–$13) | 2% ($0–$1) | CRMD | |
| Beta / 30D Volatility | 1.20β · 107% Vol | 1.18β · 153% Vol | CRMD | |
| Unified Institutional Score | 53.2 / 100 (HOLD) | 41.7 / 100 (SELL) | CRMD | |
| Trailing 12M Revenue (USD) | $1.05B | N/A | Scale | |
| Gross Profit Margin (TTM) | 87.4% | N/A | Quality | |
| PEG Ratio & EV / Revenue | 3.79x PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $785M ($535M Net Cash) | N/A ($6.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CRMD +24.89 pp
3M Horizon
CRMD +26.06 pp
6M Horizon
CRMD +29.54 pp
1Y Horizon
CRMD +27.51 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRMD Revenue | OGEN Revenue | CRMD Op. Margin | OGEN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -6250.4% | N/A | CRMD |
| FY2019 | $0M | N/A | -7416.3% | N/A | CRMD |
| FY2020 | $0M | N/A | -11378.4% | N/A | CRMD |
| FY2021 | $0M | $0M | -15417.5% | -18130.3% | CRMD |
| FY2022 | $0M | $0M | -46819.9% | -10964.6% | OGEN |
| FY2023 | N/A | $0M | N/A | -55519.9% | OGEN |
| FY2024 | $40M | N/A | -51.4% | N/A | CRMD |
| FY2025 | $310M | N/A | 48.2% | N/A | CRMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CRMD
BREAKDOWN
Current IV
56.3%
IV Percentile
25th %ile
Put/Call OI Skew
0.69x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
OGEN
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact OGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CRMD Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
46.4% of Rev ($488M)
90D Engineering Disclosures
0 Published
OGEN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CRMD vs OGEN Key Questions & Quantitative Answers
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas OGEN carries 41.7/100 (SELL) at $0.19 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile OGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRMD leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with OGEN at -91.3% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRMD cumulative revenue shifted +675.0% while OGEN shifted N/A. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OGEN.
CRMD screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas OGEN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus OGEN (-1307.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, OGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 153% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
OGEN vs CRMD · Reverse Pair
CRMD vs VTVT
· Sector Peer
CRMD vs CAPR
· Sector Peer
OGEN vs VTVT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking